These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3276987)

  • 21. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.
    Creager MA; Pariser KM; Winston EM; Rasmussen HM; Miller KB; Coffman JD
    Am Heart J; 1984 Aug; 108(2):370-3. PubMed ID: 6380254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifedipine treatment of Raynaud's phenomenon in a paediatric age.
    Matucci Cerinic M; Falcini F; Bartolozzi G; Volpi M
    Int J Clin Pharmacol Res; 1985; 5(1):67-9. PubMed ID: 3997315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Raynaud's phenomenon and calcium blocking agents. A preliminary open study with flunarizine].
    Centonze V; Campanale G; Vino M; Caporaletti P; Magrone D; Russo P; Di Bari M; Loragno V; Albano O
    Clin Ter; 1991 Apr; 137(2):77-82. PubMed ID: 1828407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasodilator drugs and peripheral vascular disease.
    Drug Ther Bull; 1972 Nov; 10(23):91-2. PubMed ID: 4144248
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of peripheral arterial insufficiency with inositoli nicotinas (Hexanicit).
    Hentzer E
    Scand J Clin Lab Invest Suppl; 1967; 99():226-32. PubMed ID: 4862834
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute effects of sublingual nifedipine in patients with Raynaud's phenomenon.
    Gush RJ; Taylor LJ; Jayson MI
    J Cardiovasc Pharmacol; 1987 May; 9(5):628-31. PubMed ID: 2439846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
    Smith CD; McKendry RJ
    Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nifedipine treatment for Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Arthritis Rheum; 1984 Aug; 27(8):959-60. PubMed ID: 6466401
    [No Abstract]   [Full Text] [Related]  

  • 31. Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon.
    Kahan A; Foult JM; Weber S; Amor B; Menkes CJ; Degeorges M
    Eur Heart J; 1985 Aug; 6(8):702-5. PubMed ID: 4054140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Kelbaek H; Hartling OJ; Nielsen SL
    Am Heart J; 1986 Apr; 111(4):742-5. PubMed ID: 3513504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raynaud's phenomenon and nifedipine.
    Kraus A
    J Rheumatol; 1989 Jul; 16(7):1013. PubMed ID: 2597264
    [No Abstract]   [Full Text] [Related]  

  • 34. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.
    Denton CP; Bunce TD; Dorado MB; Roberts Z; Wilson H; Howell K; Bruckdorfer KR; Black CM
    Rheumatology (Oxford); 1999 Apr; 38(4):309-15. PubMed ID: 10378706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasodilators: minoxidil and drugs used in peripheral vascular and cerebral disorders.
    Lowe GD
    Br Med J (Clin Res Ed); 1983 Apr; 286(6373):1262-4. PubMed ID: 6404416
    [No Abstract]   [Full Text] [Related]  

  • 37. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
    Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
    J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [SUBCUTANEOUS INJECTIONS OF CARBON DIOXIDE AND ROYAT THERMAL GASES IN ARTERIAL DISEASES (ANGINA PECTORIS, INTERMITTENT CLAUDICATION, RAYNAUD'S DISEASE, HEADACHE OF HYPERTENSIVES, ETC.)].
    LIAN C
    Sem Hop; 1963 Dec; 39():2924-7. PubMed ID: 14097963
    [No Abstract]   [Full Text] [Related]  

  • 39. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Attempts of treatment of peripheral blood circulation disorders including thromboembolic and hyperlipemic conditions with pentosanpolysulfoester (PPE)].
    Szirmai E; Celander DR
    Pharmazie; 1968 Sep; 23(9):501-2. PubMed ID: 4180427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.